News & Updates
Filter by Specialty:

Subcutaneous amivantamab compares favourably with intravenous dosing in EGFR-mutant NSCLC
In previously treated patients with EGFR-mutated advanced non-small-cell lung cancer (NSCLC), subcutaneous (SC) amivantamab combined with lazertinib shows noninferior pharmacokinetic and efficacy profiles compared with the approved intravenous (IV) formulation of amivantamab, according to the phase III PALOMA-3 trial.
Subcutaneous amivantamab compares favourably with intravenous dosing in EGFR-mutant NSCLC
18 Jun 2024
NMR helps tailor treatment for smoking cessation in smokers with COPD
Among smokers with chronic obstructive pulmonary disease (COPD), use of varenicline seems better than bupropion in normal metabolizers, but bupropion displays similar efficacy and less side effects in slow metabolizers, reports a study.
NMR helps tailor treatment for smoking cessation in smokers with COPD
18 Jun 2024
Consolidation durvalumab poised to become ‘new standard’ for limited-stage SCLC
Consolidation treatment with the PD-L1 antibody durvalumab following concurrent chemoradiotherapy significantly prolonged overall (OS) and progression-free survival (PFS) in patients with limited-stage small-cell lung cancer (SCLC), as shown in the interim analysis of the phase III ADRIATIC trial.
Consolidation durvalumab poised to become ‘new standard’ for limited-stage SCLC
14 Jun 2024
Nivolumab plus chemo offers prolonged survival in resectable NSCLC
Patients with resectable nonsmall cell lung cancer (NSCLC) enjoy sustained survival from neoadjuvant nivolumab when added to chemotherapy compared with chemotherapy alone, as seen in the 4-year analysis from the phase III CheckMate 816 study.
Nivolumab plus chemo offers prolonged survival in resectable NSCLC
14 Jun 2024
6-lead ECG device simplifies QT interval monitoring in RR-TB
A handheld, 6-lead electrocardiographic (ECG) device may be an effective triage test that could reduce the need for 12-lead ECG monitoring in resource-limited, rifampin-resistant tuberculosis (RR-TB) treatment settings, according to a diagnostic prospective cohort study.